Tango Therapeutics plans to begin a frontline pancreatic cancer phase three study in the first half of next year, enrolling 240 patients in each arm with response rate and progression-free survival as dual primary endpoints.
TNGX · Tango Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Tango Therapeutics reported 82% ORR and 88% PFS for vopimetostat plus daraxonrasib in pancreatic cancer, plans Phase 3 in first half of 2027, and held $977.5 million in cash, cash equivalents and marketable securities at September 30, 2026.
Tango Therapeutics reported an 82% ORR for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with MTAP-deleted/RAS-mutant PDAC and plans a global, randomized registrational trial in first-line PDAC in the first half of 2027.
Tango's updated data for vopametistat with Diracxon RASIB in pancreatic cancer show an objective response rate of 82% among 22 patients with metastatic pancreatic cancer and a nine-month progression-free survival rate of 88%. The company plans to start a Phase III study in first-line MTAP-deleted pancreatic cancer, anticipated to enroll 484 patients, in the first half of 2027. It also plans to start a study in MTAP wild-type pancreatic cancer in the first half of 2027.
Tango Therapeutics reported an 82% objective response rate for vopimetostat plus daraxonrasib in 22 efficacy-evaluable patients with second line or third line MTAP-deleted/RAS-mutant pancreatic cancer. It plans to start a randomized registrational trial in front-line MTAP-deleted pancreatic cancer in the first half of 2027. It also intends to reduce its workforce by approximately 14% as part of a strategic reprioritization.